CannabisNewsBreaks

ThursdayJul 06, 2023 3:54 pm

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces $3M Common Stock Private Placement

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, has received strategic investment support. According to an announcement from the company, it has received investments from four funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management firm with more than $2 billion in managed assets. The announcement also noted that additional contributions were received from three unrelated investors. In total, the company has received an estimated $3 million in gross proceeds. “The…

Continue Reading

ThursdayJul 06, 2023 12:48 pm

CannabisNewsBreaks – Alt Pro Expo to Take the Stage in Dallas

Following successful events in North and South America, the Alternative Products Expo (“Alt Pro Expo”), a production of ZJ Events, is coming to the vibrant city of Dallas, Texas. The Dallas Expo 2023 is set to take place at the Kay Bailey Hutchison Convention Center in the heart of downtown from July 13-15, 2023. The center of retail distribution in the American southwest, Dallas is well on its way to becoming one of the largest hubs in the alternative products industry. The burgeoning space is now generating $25 billion in annual revenues in the vaping, hemp and smoke shop segments…

Continue Reading

MondayJul 03, 2023 12:13 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL…

Continue Reading

ThursdayJun 22, 2023 11:49 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (“EB”). According to the announcement, of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in…

Continue Reading

TuesdayJun 20, 2023 2:14 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21.  The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods…

Continue Reading

FridayJun 16, 2023 1:51 pm

CannabisNewsBreaks – Lift Events Partners with Arcview Group for Upcoming US Cannabis, Investment Event

Lift Events announced a new partnership with the Arcview Group as it anticipates its upcoming Lift San Francisco event, slated for Aug. 3–4, 2023. The company announced that the Lift Cannabis Business Conference, slated for Aug. 3, will be a combined event with a new Investment Summit presented in partnership with the Arcview Group, a recognized pioneer in cannabis and hemp industry investment content. According to the announcement, the “game-changing” partnership will prioritize social justice and responsibility, with the Arcview Group providing a broad spectrum of programs and services across a vertically integrated organization. In addition, the Lift San Francisco…

Continue Reading

FridayJun 16, 2023 11:52 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study…

Continue Reading

MondayJun 12, 2023 1:12 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held senior positions with companies in the biotechnology, medical devices and software-as-a-service industries. As a consultant with NOW CFO, one of his current clients is a publicly traded clinical-stage biopharmaceutical company. Former clients include a medical device maker for which Mike collaborated with independent auditors and investment bankers through the completion of an initial public offering. The client began trading on…

Continue Reading

FridayJun 09, 2023 10:42 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. “The new patents will add to Lexaria’s growing portfolio and, upon award, will bring the total number of patents granted worldwide to 32, with several more pending,” a recent article reads. “Lexaria’s new patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Agents. This patent is the fifth awarded in Japan, strengthening the company’s growing…

Continue Reading

TuesdayJun 06, 2023 2:54 pm

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Notice of Allowance for Patent on IGC-501

IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the formulation for treating seizures is protected in the U.S., Canada and certain European countries. IGC provided animal data (dogs) on the reduction in the number of seizures by using a combination of cannabidiol (“CBD”) and phenobarbital versus either alone. The company intends to pursue the…

Continue Reading